Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

Abstract

Despite the protective role that blood brain barrier plays in shielding the brain, it limits the access to the central nervous system (CNS) which most often results in failure of potential therapeutics designed for neurodegenerative disorders. Neurodegenerative diseases such as Spinal Muscular Atrophy (SMA), in which the lower motor neurons are affected, can benefit greatly from introducing the therapeutic agents into the CNS. The purpose of this video is to demonstrate two different injection paradigms to deliver therapeutic materials into neonatal mice soon after birth. One of these methods is injecting directly into cerebral lateral ventricles (Intracerebroventricular) which results in delivery of materials into the CNS through the cerebrospinal fluid. The second method is a temporal vein injection (intravenous) that can introduce different therapeutics into the circulatory system, leading to systemic delivery including the CNS. Widespread transduction of the CNS is achievable if an appropriate viral vector and viral serotype is utilized. Visualization and utilization of the temporal vein for injection is feasible up to postnatal day 6. However, if the delivered material is intended to reach the CNS, these injections should take place while the blood brain barrier is more permeable due to its immature status, preferably prior to postnatal day 2. The fully developed blood brain barrier greatly limits the effectiveness of intravenous delivery. Both delivery systems are simple and effective once the surgical aptitude is achieved. They do not require any extensive surgical devices and can be performed by a single person. However, these techniques are not without challenges. The small size of postnatal day 2 pups and the subsequent small target areas can make the injections difficult to perform and initially challenging to replicate.

Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy

“…Viral delivery was performed by intravenous injection into the superficial facial vein. MO E1v11 delivery was performed by intracerebroventricular injection using methods described previously (33,34). Time-to-right assays were performed between P14 and P23 by placing the animal on its back and timing its ability to turn over and stand on all 4 legs, with 30 or more seconds to right qualifying as a failure.…”

Hearing Loss and Otopathology Following Systemic and Intracerebroventricular Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin

“…The volume of HPβCD injected into the ventricles was less than 4 μL. ICV injection was performed using standard methods (Glascock et al 2011;Tsuneki et al 2008). In brief, animals were anesthetized with 2 % isoflurane then secured in a stereotactic frame.…”

A new method to measure autophagy flux in the nervous system

“…This method is based on the manual injection of concentrated AAVs into the ventricle of newborn mice, which led to the diffusion of the viral particles through the cerebrospinal fluid, generating a massive and global transduction of neurons of the nervous system. 17, 18 The specificity of the expression was obtained through the use of a particular serotype of AAVs, serotype 2, which has a high tropism for neurons, 19,20 but it also can transduce oligodendrocytes to a lower extent. 21 Importantly, there are many different AAV serotypes available that could be used to transduce other cell types of the nervous system (Fig.…”